CDXC Company Profile and Key Details
ChromaDex Corporation
CDXC Stock Price Chart
Stock Price Today
ChromaDex Corporation (CDXC) stock surged +2.53%, trading at $6.09 on NASDAQ, up from the previous close of $5.94. The stock opened at $6.06, fluctuating between $6.01 and $6.23 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Company Information
| Employees | 106 |
| Beta | 1.88 |
| Sales or Revenue | $83.57M |
| 5Y Sales Change% | 0.943% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
ChromaDex Corporation (NASDAQ: CDXC) stock price is $6.09 in the last trading session. During the trading session, CDXC stock reached the peak price of $6.23 while $6.01 was the lowest point it dropped to. The percentage change in CDXC stock occurred in the recent session was 2.53% while the dollar amount for the price change in CDXC stock was $0.15.
The NASDAQ listed CDXC is part of Biotechnology industry that operates in the broader Healthcare sector. ChromaDex Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Andrew Shao Ph.D.
Senior Vice President of Global Regulatory & Scientific Affairs
Tom Shumaker
Managing Director of LifeSci Advisors
Mr. Frank Louis Jaksch Jr.
Co-Founder & Chairman
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Mr. Robert N. Fried
Chief Executive Officer & Director
Alex Worsham
Vice President of Global Marketing & Communications
Heather Van Blarcom
Senior Vice President of Legal & Corporation Sec.
David Kroes
Senior Vice President of People Matters
Ms. Brianna Gerber
Senior Vice President of Fin., VP of Investor Relations & Interim Chief Financial Officer
Ms. Chu Yan
Managing Director of Asia Pacific
Mr. Fadi Karam
Chief Marketing Officer
CDXC's closing price is 347.79% higher than its 52-week low of $1.36 where as its distance from 52-week high of $7.97 is -23.59%.
Number of CDXC employees currently stands at 106.
Official Website of CDXC is: https://www.chromadex.com
CDXC could be contacted at phone 310 388 6706 and can also be accessed through its website. CDXC operates from 10900 Wilshire Boulevard, Los Angeles, CA 90024, United States.
CDXC stock volume for the day was 402.89K shares. The average number of CDXC shares traded daily for last 3 months was 1.37M.
The market value of CDXC currently stands at $465.17M with its latest stock price at $6.09 and 76.38M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com